Key Takeaways Broad adoption of non-opioid pain devices and digital transformation could accelerate recurring high-margin revenue and expand market share beyond expectations. New leadership, product innovation, and operational discipline position Zynex for sustained top-line growth, improved margins, and greater strategic interest from partners.Read more
Key Takeaways Unresolved reimbursement issues and market reliance may hinder Zynex's sales growth and margin stability despite demographic and regulatory tailwinds. Regulatory uncertainty, operational challenges, and financial pressures threaten successful execution and sustainable earnings improvement.Read more
Key Takeaways Rising demand for non-opioid pain management and regulatory trends support Zynex's expansion into new markets and product lines. Operational restructuring and leadership changes are positioned to improve margins, cash flow, and drive future earnings growth.Read more
Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain, and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; and M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body; and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, braces for rehabilitation support for knee and wrist, and Dynacomp for cold compression therapy. Further, it develops Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser photoplethysmographic patient monitoring device; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; and fluid monitoring and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.
